Alana Hippensteele, Managing Editor

The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.

The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.

Depression can affect the trajectory of treatment and associated outcomes.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.

Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.

Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

During a fireside chat, USP CEO Ronald T. Piervincenzi, PhD, and the Honorable Dr. Oh Yu-Kyoung, Minister of MFDS, Republic of Korea, discuss interruptions to the medical supply chain and the interventions used.

The impact that socioeconomic inequities can have on a child’s hippocampal volume may have implications for their success and experience pursuing educational endeavors.

Illegal online sellers threaten the health, privacy, and security of patients by failing to comply with the laws of the jurisdiction in which they are located, or the jurisdiction in which they are selling their medicines.

The advent of pharmacy-based community health workers has helped to expand and codify the pre-existing community-based efforts of pharmacy technicians to reach even outside of medication access.

The final approval was based on efficacy and safety data from the phase 3 REST-ON study.

Molidustat oral suspension is also the first approval for cats under the FDA’s expanded conditional approval pathway.

Even before the Dobbs ruling overturned country-wide reproductive rights, the oncology field was already facing a dearth of maternal care access challenges.

Limitations on a woman’s options when pregnant and diagnosed with cancer can directly impact her ability to save her own life and preserve her fertility for future pregnancies.

Choosing the best biosimilar based on reimbursement can be challenging.

The gene-editing technology has been used successfully in a pediatric patient with T-cell ALL.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

These data support using this combination therapy as a new first-line treatment option in patients with previously untreated metastatic or unresectable BTC.

This drug is the first to control complement factor C5a, which is a protein that plays a significant but potentially harmful role in the body's immune response.

Creating a safe environment for LGBTQ+ patients through the use of trauma informed care is critical to ensuring they feel comfortable returning to the clinic in the future.